----

----

----

| Florida                                                                  |   |    65-0736042                   |
|--------------------------------------------------------------------------|--------|------------------------------------------------|
| (State      or Other Jurisdiction of      Incorporation or Organization) |   | (I.R.S.      Employer Identification      No.) |
|                                                                          |   |                                                |

| c/o      Olshan Grundman Frome et al.                                                                                                                                |   |            |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-----------------|
| 65 East 55th Street, New York, New      York                     |   | 10022           |
| (Address of Principal Executive      Offices)                                                                                                                        |   | (Zip      Code) |

| Large      accelerated filer                       |  ̈ | Accelerated      filer         |  ̈ |
|----------------------------------------------------|--------|--------------------------------|--------|
| Non-accelerated      filer                         |  ̈ | Smaller      reporting company | x      |
| (Do      not check if a smaller reporting company) |   |                           |   |

----

TABLE OF CONTENTS

|   |         | PART      I                                                          | Page   |   |
|--------|--------------|----------------------------------------------------------------------|--------|--------|
|   | Item      1. | FINANCIAL      STATEMENTS                                            | 1      |   |
|   | Item      2. | MANAGEMENT’S      DISCUSSION AND ANALYSIS OR PLAN OF OPERATION | 7      |   |
|   | Item      3. | QUANTITATIVE      AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.     | 8      |   |
|   | Item      4. | CONTROLS      AND PROCEDURES                                         |   |   |
|   |         | PART      II                                                         |   |   |
|   | Item      1. | LEGAL      PROCEEDINGS                                               | 9      |   |
|   | Item      2. | UNREGISTERED      SALES OF EQUITY SECURITIES AND USE OF PROCEEDS     | 9      |   |
|   | Item      3. | DEFAULTS      UPON SENIOR SECURITIES                                 | 9      |   |
|   | Item      4. | SUBMISSION      OF MATTERS TO A VOTE OF SECURITIY HOLDERS            | 9      |   |
|   | Item      5. | OTHER      INFORMATION                                               | 9      |   |
|   | Item      6. | EXHIBITS                                                             | 9      |   |
|   | SIGNATURES   |                                                                 |   |   |
|   | EXHIBITS     |                                                                 |   |   |

----

----

----

| Balance    sheet                   | 1      |
|------------------------------------|--------|
|                               |   |
| Statements of      operations      | 2      |
|                               |   |
| Statements of cash      flows      | 3-4    |
|                               |   |
| Notes to financial      statements | 5-6    |
|                               |   |

----

----

|                                                                      |   | UNAUDITED      |     |   |              |   |
|---------------------------------------------------------------------------|--------|----------------|----------|--------|-------------------|--------|
| ASSETS                                                                    |   | MARCH      31, |     |   | DECEMBER      31, |   |
|                                                                      |   | 2009           |     |   | 2008              |   |
|                                                                      |   |           |     |   |              |   |
|                                                                      |   |           |     |   |              |   |
| CURRENT      ASSETS:                                                      |   |           |     |   |              |   |
|                                                                      |   |           |     |   |              |   |
| Cash                                                                      |   | $              | 28       |   |              | $      | 103 |   |
|                                                                      |   |           |     |   |              |   |   |   |
| Total      current assets                                                 |   |           | 28       |   |              |   | 103 |   |
|                                                                      |   |           |     |   |              |   |   |   |
| TOTAL      ASSETS                                                         |   | $              | 28       |   |              | $      | 103 |   |
|                                                                      |   |           |     |   |              |   |   |   |
|                                                                      |   |           |     |   |              |   |   |   |
| LIABILITIES      AND STOCKHOLDERS’ DEFICIENCY                       |   |           |     |   |              |   |   |   |
|                                                                      |   |           |     |   |              |   |   |   |
|                                                                      |   |           |     |   |              |   |   |   |
| CURRENT      LIABILITIES:                                                 |   |           |     |   |              |   |   |   |
|                                                                      |   |           |     |   |              |   |   |   |
| Accounts      payable and accrued expenses                                |   | $              | 106,400  |   |              | $      | 103,100 |   |
| Accounts      payable - related party                                     |   |           | 25,470   |   |              |   | 23,649 |   |
| Notes      payable - related party, in default                            |   |           | 24,409   |   |              |   | 24,409 |   |
| Notes      payable - related party                                        |   |           | 48,450   |   |              |   | 48,450 |   |
|                                                                      |   |           |     |   |              |   |   |   |
| Total      current liabilities                                            |   |           | 204,729  |   |              |   | 199,608 |   |
|                                                                      |   |           |     |   |              |   |   |   |
| STOCKHOLDERS’      DEFICIENCY:                                      |   |           |     |   |              |   |   |   |
|                                                                      |   |           |     |   |              |   |   |   |
| Preferred      stock, par value $.0001 per share; 10,000,000 shares       |   |           |     |   |              |   |   |   |
|   authorized;      none issued and outstanding                  |   |           | --       |   |              |   | -- |   |
|   as      of March 31, 2009 and December 31, 2008, respectively |   |           |     |   |              |   |   |   |
| Common      stock, par value $.0001 per share; 50,000,000 shares          |   |           |     |   |              |   |   |   |
|   authorized;      392,457 shares issued and outstanding        |   |           | 40       |   |              |   | 40 |   |
|   as      of March 31, 2009 and December 31, 2008, respectively |   |           |     |   |              |   |   |   |
| Additional      paid-in capital                                           |   |           | 137,008  |   |              |   | 137,008 |   |
| Deficit      accumulated during the development stage                     |   |           | (341,749 | )      |              |   | (336,553 | ) |
|                                                                      |   |           |     |   |              |   |   |   |
|   Total      stockholders’ deficiency                     |   |           | (204,701 | )      |              |   | (199,505 | ) |
|                                                                      |   |           |     |   |              |   |   |   |
|   TOTAL      LIABILITIES AND STOCKHOLDERS’ DEFICIENCY     |   | $              | 28       |   |              | $      | 103 |   |
|                                                                      |   |           |     |   |              |   |   |   |

----

----

|                                       |   |                                              |    |   |                        |   |    |                |   |
|--------------------------------------------|--------|---------------------------------------------------|---------|--------|-----------------------------|--------|---------|---------------------|--------|
|                                       |   |                                              |    |   | FOR      THE PERIOD         |   |
|                                       |   |                                              |    |   | MARCH      21, 1997         |   |
|                                       |   |  THREE      MONTHS ENDED MARCH 31, |    |   | (DATE      OF INCEPTION) TO |   |
|                                       |   | 2009                                              |    |   | 2008                        |   |    | MARCH      31, 2009 |   |
|                                       |   |                                              |    |   |                        |   |    |                |   |
| DEVELOPMENT      STAGE REVENUES            |   | $                                                 | 0       |   |                        | $      | 0       |                |   | $ | 24,728 |   |
|                                       |   |                                              |    |   |                        |   |    |                |   |   |   |   |
| DEVELOPMENT      STAGE EXPENSES:           |   |                                              |    |   |                        |   |    |                |   |   |   |   |
|                                       |   |                                              |    |   |                        |   |    |                |   |   |   |   |
| Accounting      and Auditing               |   |                                              | 3,100   |   |                        |   | 1,500   |                |   |   | 138,971 |   |
| Advertising                                |   |                                              | 0       |   |                        |   | 0       |                |   |   | 30,560 |   |
| Bank      charges                          |   |                                              | 75      |   |                        |   | 75      |                |   |   | 1,265 |   |
| Consulting      fees                       |   |                                              | 0       |   |                        |   | 0       |                |   |   | 5,082 |   |
| Legal      fees                            |   |                                              | 0       |   |                        |   | 0       |                |   |   | 55,947 |   |
| Licenses      and taxes                    |   |                                              | 0       |   |                        |   | 200     |                |   |   | 2,782 |   |
| Meals      and entertainment               |   |                                              | 0       |   |                        |   | 0       |                |   |   | 5,248 |   |
| Miscellanous      expenses                 |   |                                              | 0       |   |                        |   | 0       |                |   |   | 1,828 |   |
| Office      general                        |   |                                              | 0       |   |                        |   | 0       |                |   |   | 10,052 |   |
| Payroll      and commissions               |   |                                              | 0       |   |                        |   | 0       |                |   |   | 14,430 |   |
| Shareholder      related services (EDGAR ) |   |                                              | 0       |   |                        |   | 1,424   |                |   |   | 3,085 |   |
| Transfer      agent fees                   |   |                                              | 200     |   |                        |   | 888     |                |   |   | 21,794 |   |
| TOTAL      DEVELOPMENT STAGE EXPENSES      |   |                                              | 3,375   |   |                        |   | 4,087   |                |   |   | 291,044 |   |
|                                       |   |                                              |    |   |                        |   |    |                |   |   |   |   |
| LOSS      FROM OPERATIONS                  |   |                                              | (3,375  | )      |                        |   | (4,087  | )                   |   |   | (266,316 | ) |
|                                       |   |                                              |    |   |                        |   |    |                |   |   |   |   |
| LOSS      ON INVESTMENT - HEALTHCARE       |   |                                              | 0       |   |                        |   | 0       |                |   |   | (50,016 | ) |
|                                       |   |                                              |    |   |                        |   |    |                |   |   |   |   |
| INTEREST      EXPENSE                      |   |                                              | (1,821  | )      |                        |   | (1,553  | )                   |   |   | (25,417 | ) |
|                                       |   |                                              |    |   |                        |   |    |                |   |   |   |   |
|                                       |   |                                              |    |   |                        |   |    |                |   |   |   |   |
| NET      LOSS                              |   | $                                                 | (5,196  | )      |                        | $      | (5,640  | )                   |   | $ | (341,749 | ) |
|                                       |   |                                              |    |   |                        |   |    |                |   |   |   |   |
| LOSS      PER COMMON SHARE                 |   |                                              |    |   |                        |   |    |                |   |   |   |   |
| Basic      & diluted                   |   | $                                                 | (0.01   | )      |                        | $      | (0.01   | )                   |   |   |   |   |
| Weighted-average      number of common     |   |                                              |    |   |                        |   |    |                |   |   |   |   |
|  shares      outstanding              |   |                                              | 392,457 |   |                        |   | 392,457 |                |   |   |   |   |
|                                       |   |                                              |    |   |                        |   |    |                |   |   |   |   |
|                                       |   |                                              |    |   |                        |   |    |                |   |   |   |   |

----

----

|                                                    |   |  UNAUDITED               |   |   | FOR      THE PERIOD      |   |
|---------------------------------------------------------|--------|-------------------------------|--------|--------|--------------------------|--------|
|                                                    |   |  THREE      MONTHS ENDED |   |   | MARCH      21, 1997      |   |
|                                                    |   |  MARCH 31,          |   |   | (DATE      OF INCEPTION) |   |
| OPERATING      ACTIVITIES                               |   | 2009                          |   |   | 2008                     |   |   | TO      MARCH 31, 2009 |   |
|                                                    |   |                          |   |   |                     |   |   |   |   |
| Net      loss                                           |   | $                             | (5,196 | )      |                     | $      | (5,340 | ) |   | $ | (341,749 | ) |
|                                                    |   |                          |   |   |                     |   |   |   |   |   |   |   |
| Adjustment      to reconcile net loss to net cash       |   |                          |   |   |                     |   |   |   |   |   |   |   |
| used      by operations                                 |   |                          |   |   |                     |   |   |   |   |   |   |   |
| Shares      issued for consulting services              |   |                          | 0      |   |                     |   | 0 |   |   |   | 36,148 |   |
| Shares      issued for termination of HMC               |   |                          | 0      |   |                     |   | 0 |   |   |   | 50,000 |   |
|                                                    |   |                          |   |   |                     |   |   |   |   |   |   |   |
| Changes      in assets and liabilities                  |   |                          |   |   |                     |   |   |   |   |   |   |   |
| Increase      in accounts payable and accrued expenses  |   |                          | 3,300  |   |                     |   | 2,962 |   |   |   | 106,400 |   |
| Increase      in accounts payable and accrued expenses  |   |                          |   |   |                     |   |   |   |   |   |   |   |
|     -  related      party |   |                          | 1,821  |   |                     |   | 1,553 |   |   |   | 25,470 |   |
|                                                    |   |                          |   |   |                     |   |   |   |   |   |   |   |
| Net      cash used by operating activities              |   |                          | (75    | )      |                     |   | (825 | ) |   |   | (123,731 | ) |
|                                                    |   |                          |   |   |                     |   |   |   |   |   |   |   |
| FINANCING      ACTIVITES                                |   |                          |   |   |                     |   |   |   |   |   |   |   |
| Proceeds      from promissory notes                     |   |                          | 0      |   |                     |   | 750 |   |   |   | 72,859 |   |
| Proceeds      from issuance of common stock             |   |                          | 0      |   |                     |   | 0 |   |   |   | 50,900 |   |
|                                                    |   |                          |   |   |                     |   |   |   |   |   |   |   |
| Net      cash provided by financing activites           |   |                          | 0      |   |                     |   | 750 |   |   |   | 123,759 |   |
|                                                    |   |                          |   |   |                     |   |   |   |   |   |   |   |
| INCREASE  IN      CASH                        |   |                          | (75    | )      |                     |   | (75 | ) |   |   | 28 |   |
|                                                    |   |                          |   |   |                     |   |   |   |   |   |   |   |
| CASH,      BEGINNING OF PERIOD                          |   |                          | 103    |   |                     |   | 84 |   |   |   | 0 |   |
|                                                    |   |                          |   |   |                     |   |   |   |   |   |   |   |
| CASH,      END OF PERIOD                                |   | $                             | 28     |   |                     | $      | 9 |   |   | $ | 28 |   |
|                                                    |   |                          |   |   |                     |   |   |   |   |   |   |   |
|                                                    |   |                          |   |   |                     |   |   |   |   |   |   |   |
|                                                    |   |                          |   |   |                     |   |   |   |   |   |   |   |
|                                                    |   |                          |   |   |                     |   |   |   |   |   |   |   |
|                                                    |   |                          |   |   |                     |   |   |   |   |   |   |   |

----

----

|                                                  |   |                          |   |   |                     |   |   | FOR      THE PERIOD |   |
|-------------------------------------------------------|--------|-------------------------------|--------|--------|--------------------------|--------|--------|---------------------|--------|
|                                                  |   |  UNAUDITED               |   |   | MARCH      21, 1997      |   |
|                                                  |   |  THREE      MONTHS ENDED |   |   | (DATE      OF INCEPTION) |   |
|                                                  |   |  MARCH      31,          |   |   | TO                       |   |
|                                                  |   | 2009                          |   |   | 2008                     |   |   | MARCH 31, 2009      |   |
|                                                  |   |                          |   |   |                     |   |   |                |   |
| Supplemental      cash flow information:              |   |                          |   |   |                     |   |   |                |   |
| Interest      paid                                    |   | $                             | 0      |   |                     | $      | 0      |                |   | $ | 0 |   |
| Income      taxes paid                                |   | $                             | 0      |   |                     | $      | 0      |                |   | $ | 0 |   |
|                                                  |   |                          |   |   |                     |   |   |                |   |   |   |   |
| Noncash      investing and financing activities:      |   |                          |   |   |                     |   |   |                |   |   |   |   |
| Shares      issued to founder for consulting services |   | $                             | 0      |   |                     | $      | 0      |                |   | $ | 81 |   |
| Shares      issued for legal services rendered        |   | $                             | 0      |   |                     | $      | 0      |                |   | $ | 500 |   |
|                                                  |   |                          |   |   |                     |   |   |                |   |   |   |   |

----

----

| 1.   | ORGANIZATION |
|----------------|--------------|

|   | Interim      Financial Information - The unaudited condensed financial      statements  have  been       prepared  by      the  Company  pursuant  to      the  rules  and regulations of the Securities and      Exchange Commission. The information furnished herein reflects all      adjustments  (consisting of      normal  recurring  accruals and      adjustments)  which are,  in      the  opinion  of  management,  necessary  to      fairly present the operating results for the respective      periods.  Certain information and footnote disclosures normally      presented in annual financial statements prepared in accordance with      accounting principles generally accepted in the United States of America      have been omitted pursuant to such rules and regulations.  The      condensed financial statements should be read in conjunction with the      description of business and management’s plan of operations, contained in      the Company's Annual Report on Form 10-KSB for the year ended December 31,      2008.  The results of operations for the  three months      ended March 31, 2009 are not necessarily indicative of the results that      may be expected for the year ending December 31, 2009, or for any future      period.  In the opinion of management, the accompanying      financial statements of Centracan, Inc., contains all adjustments      necessary to present fairly the Company’s financial position as of March      31, 2009 and December 31, 2008, the statements of operations for      the  three months ended March 31, 2009 and 2008 and cash flows      for the three months ended March 31, 2009 and  2008. |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | DESCRIPTION      OF BUSINESS |
|--------|------------------------------|

|   | Premier      Supplements, Corp. (“the Company”) was incorporated on March 21, 1997      under the laws of the State of Florida.  On May 15, 1998 the      Company changed its name to Centracan, Inc.  The Company’s      operations have been devoted primarily to structuring and positioning      itself to take advantage of opportunities available in the pharmaceutical      industry.  The Company intends to grow through internal      development, strategic alliances and acquisitions of existing business.      The Company is a development stage company and has had limited      activity. |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | GOING      CONCERN |
|--------|--------------------|

|   | The      accompanying financial statements have been prepared on a going concern      basis, which contemplates the realization of assets and the      satisfaction of liabilities in the normal    course of      business.  As reflected in the financial statements, development      stage losses from |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

|   | March      21, 1997 (inception) to March 31, 2009 aggregated $341,749 and raise      substantial doubt about the Company’s ability to continue as a going      concern.  The Company’s cash flow requirements during this      period have been met by contributions of capital and debt      financing.  Management’s plans include the potential development      of its own business or merging with an operating company.  The      Company anticipates that financing will be required until such time that      the Company has been able to develop its own business or find an      appropriate merger candidate.  Currently, the Company can not      determine when either will occur and as such the Company will need to      obtain financing to cover its costs for the foreseeable      future.  No assurance can be given that these sources of      financing will continue to be available.  If the Company is      unable to generate profits, or unable to obtain additional funds for its      working capital needs, it may have to cease  operations. |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.   | ACCOUNTS      PAYABLE AND ACCRUED EXPENSES |
|----------------|--------------------------------------------|

|                                               |   | March      31, 2009 |    |   | December      31, 2008 |   |
|----------------------------------------------------|--------|--------------------------|---------|--------|-----------------------------|--------|
| Accrued      expenses, primarily professional fees |   |                     | 106,400 |   |                        |   | 103,100 |   |
| Account      payable – to related parties    |   | $                        | 25,470  |   |                        | $      | 23,649 |   |
| Total      accounts payable and accrued expenses   |   | $                        | 131,870 |   |                        | $      | 126,749 |   |

| 3.   | NOTE      PAYABLE – RELATED PARTY |
|----------------|-----------------------------------------|

----

----

----

----

|                                 | CENTRACAN      INCORPORATED |                          |
|--------------------------------------|-----------------------------|-------------------------------|
|                                 |                        |                          |   |
| Dated:       May 14, 2009  | By:                         | /s/ Jerome      Goubeaux |   |
|                                 |                        | Jerome      Goubeaux          |   |
|                                 |                        | Chief      Executive Officer  |   |
|                                 |                        |                          |   |